Search Blog Posts
Blog Posts
Dope for Multiple Myeloma Demonstrated to Significantly Confer Di…
----- | December 18th 2009 by Алеша
Source: Native Cancer Commence Kindred MedlinePlus Topic: read more
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Tri…
Zamp BioTopics | December 17th 2009 by Zamp
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company’s PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, read more
Market Alert for Array BioPharma In. (ARRY)
Investorsoup | December 16th 2009
Array BioPharma Inc. (NASDAQ: ARRY) Array BioPharma Inc. (ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and meta read more
Myeloma transplant - Mind games
Sid's multiple myeloma journey | December 15th 2009 by Sidney Hider
During the time of my illness and especially during my autologous stem cell transplant for myeloma I was intrigued by how much mind games came into play.It was a battle at times to stay focussed on where I was, what was happening and not to let the m read more
No Title
Tanner's Journey | December 12th 2009 by Angela Walker
There's not much to post today. We went in to the clinic at 8:00 a.m. this morning and according to the numbers from yesterday's labwork, he's now neutropenic again. Hopefully he will hit bottom this weekend and will start back up so we can head hom read more
Facet Biotech And Bristol-Myers Squibb Report Promising Phase I/I…
Zamp BioTopics | December 12th 2009 by Zamp
Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed m read more
Myeloma transplant - Recovery
Sid's multiple myeloma journey | December 12th 2009 by Sidney Hider
Leaving the BMTU after my autologous stem cell transplant for myeloma was a test; the hospital was a secure base. There I had been dependent on others, now I was returning to independence. It was like cutting the umbilical chord from Mother ship.My p read more
Draw Series and Classification of MAQC-II Titty Cancer and Multip…
Новостная лента занимательных, и… | December 11th 2009 by Светлана
Microarray figures has a penetrating dimension of variables but convenient datasets on the whole compel ought to just a teeny several of samples, thereby making the retreat of such datasets provocative and challenging. In the rebuke of analyzing micr read more
Puff up Selection and Classification of MAQC-II Chest Cancer and…
News line with educational, intresting health, medical and… | December 11th 2009 by Jasmin
Microarray information has a elevated dimension of variables but on tap datasets usually induce only a small count of samples, thereby making the reading of such datasets enchanting and challenging. In the work of analyzing microarray data for the wi read more
#ASH09 Update: Multiple Myeloma
Pharma Strategy Blog | December 10th 2009 by Sally Church
In the past, single agent and double agent regimens have been a mainstay in the treatment of multiple myeloma, yet the five year survival rate has remained steadfastly low around 3-4 years, on average. Typically, younger and fitter patients do better read more
Semafore Pharmaceuticals Reports Encouraging Phase I Data At ASH…
Zamp Bionews | December 10th 2009 by Zamp
Semafore Pharmaceuticals reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of read more
Seattle Genetics Reports Data From Dacetuzumab Phase Ib Combinati…
Zamp Bionews | December 10th 2009 by Zamp
Seattle Genetics, Inc. (Nasdaq:SGEN) reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with read more
Acute Leukemia: First-In-Class Treatment
Zamp Bionews | December 10th 2009 by Zamp
EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients’ own ‘natural killer’ cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myelo read more
ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN…
Zamp Bionews | December 10th 2009 by Zamp
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (M read more
Back Pain and Multiple Myeloma
Back Pain Care | December 9th 2009 by Brian Hackett
A number of the common issues that cause back pain merge from musculoskeletal conditions and neurological conditions. But, read more
Colored Ribbons Signifying Awareness
MEDCHROME | December 9th 2009 by Sulav Shrestha
Awareness ribbons Below is a list of colored ribbons signifying awareness of cancers, diseases, abuse, addiction, preventions, etc. Pink Ribbon : 1. Breast cancer awareness 2. childhood cancer awareness Yellow Ribbon : 1. Suicide prevention 2. Bladd read more
Sid's story in LBF magazine
Sid's multiple myeloma journey | December 8th 2009 by Sidney Hider
About this time last year I was interviewed by a journalist doing research for an article to be placed in the Leukaemia and Blood Foundation of New Zealand (LBF) magazine winter edition. LBF wanted a multiple myeloma patient who had myeloma long term read more
Cast Nephropathy and plasmapheresis
Precious Bodily Fluids | December 7th 2009 by Joel Topf
Does removal of the light chains with plasmapharesis reduce the severity of cast nephropathy? We know that renal failure is a terrible prognostic factor in multiple myeloma so fixing acute renal failure is important.Renal failure comes in many differ read more
New 3-drug combo may effectively treat multiple myeloma
PharmaMics | December 7th 2009 by Emad
Researchers from Dana-Farber Cancer Institute have found that a new three-drug combination can effectively treat patients newly diagnosed with multiple myeloma, a cancer of white blood cells in the bone marrow.The three-drug combination has shown in read more
ImmunoGen reports encouraging clinical data of IMGN901
Medical News | December 6th 2009 by undertaker
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), inclu read more
Multiple myeloma responds well to new 3-drug combination
iHealthBulletin News | December 6th 2009
A new three-drug combination of Revlimid®, Velcade®, and dexamethasone has shown in a phase 1/2 clinical trial that it is a “highly effective regimen” in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood c read more
Bortezomib Shows Promise in Reducing Graft-versus-Host Disease an…
Stem Cell News and Blog | December 6th 2009 by Kelvin
A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early read more
Myeloma transplant - Days 16 to 22
Sid's multiple myeloma journey | December 6th 2009 by Sidney Hider
This is a daily diary of my autologous stem cell transplant (ASCT) for multiple myeloma compiled from my diary and my own recollections.My ASCT daily diary is over 4 postings, this is posting 4 of 4; days 16 to 22.Link to posting 1; Days -02 to 05Lin read more
The International Myeloma Foundation Says For The First Time Medi…
OncoBlog | December 5th 2009
The International Myeloma Foundation (IMF)-- supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today said presentations at... [[ This is a content summary only. Visit my web read more
Pseudogaucher cells obscuring multiple myeloma: a case report - 7…
Thalassemia Today | December 4th 2009 by BananaFancy
Pseudogaucher cells obscuring multiple myeloma: a case report 7thSpace Interactive (press release) Gaucher-like or pseudo-Gaucher cells have been noted in a variety of conditions including acute lymphoblastic leukemia, Hodgkin's disease, thalass read more
“Partnering for Cures” bringing diverse interests together
The Myelin Repair Foundation Blog | December 3rd 2009 by Justine Lam
I have been on the steering committee of FasterCures for the last five years. In the past their meetings drew participants from cutting edge medical research foundations who would discuss the systemic challenges in translational research (moving dis read more
My two m-spikes
Beth's Myeloma Blog | December 3rd 2009
I wanted to post my results, and got a little behind! Here it is: SERUM PROTEIN ELECTROPHORESIS: COMPARED TO 6/1/09, NO SIGNIFICANT CHANGE IN PREVIOUSLY CHARACTERIZED (2) IgA-LAMBDAS FROM 0.25 TO 0.26 G/dL AND FROM 0.19 TO 0.15 G/dL. The two m-spike read more
FDA fast tracks Aeterna, Keryx cancer drug
Heart Health | December 3rd 2009 by Manmeet
Canadian drugmaker Aeterna Zentaris said on Wednesday that its experimental cancer drug KRX-0401 has received fast track approval from U.S. health regulators, a move that could clear a quick path to final approval for the multiple myeloma treatment. read more
Azerbaijani embassy in Moscow hosts meeting with Azerbaijani doct…
Thalassemia Today | December 3rd 2009 by BananaFancy
APA Azerbaijani embassy in Moscow hosts meeting with Azerbaijani doctors working … APA “A modern Thalassemia Center has been built in Baku, new health facilities are being built and old medical establishments overhauled within the framework read more
Myeloma transplant - Days 12 to 15
Sid's multiple myeloma journey | December 3rd 2009 by Sidney Hider
This is a daily diary of my autologous stem cell transplant (ASCT) for multiple myeloma compiled from my diary and my own recollections.My ASCT daily diary is over 4 postings, this is posting 3 of 4; days 12 to 15.Link to posting 1; Days -02 to 05Lin read more
Subscribe To